Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) (Intermediate Risk) </= 60y. After First CR

Randomised Trial on Allogeneic Haematopoietic Stem Cell Transplantation in Patients Under the Age of 60 Years With Acute Myeloid Leukemia of Intermediate Risk in First Complete Remission and a Matched Sibling or Unrelated Donor (ETAL-1)

Hematopoietic stem cell transplantation in patients with newly diagnosed AML ≤60 years of age in intermediate risk, after first complete response in comparison to standard consolidation chemotherapy

Inclusion Criteria:

• AML in first remission
• cytological standard risk, i.e. karyotype not listed under exclusion criteria
• Identification of HLA-identical sibling or HLA-compatible related or unrelated donor (9/10 HLA-alleles matched, high resolution typing for HLA-A, B, Cw, DRB1 and DQB1)
• age: 18 - 60 years
• medically fit for allogeneic stem cell transplantation
• CR / CRi after induction therapy

Exclusion Criteria:

• core-binding factor leukemia (t(8;21), inv16)
• acute promyelocytic leukemia (t(15;17)
• complex aberrant karyotype
• karyotypes: -7; -5; del5q; t(3;3); t(6;11), t(6;9), 11q aberrations, trisomy 8 ± one single additional aberration
• pregnancy / nursing
• non-compliance